TaiMed Biologics (TWO:4147) — Market Cap & Net Worth
Market Cap & Net Worth: TaiMed Biologics (4147)
TaiMed Biologics (TWO:4147) has a market capitalization of $504.04 Million (NT$16.00 Billion) as of August 6, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #12129 globally and #442 in its home market, demonstrating a 1.90% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying TaiMed Biologics's stock price NT$59.10 by its total outstanding shares 270702425 (270.70 Million). See capital reinvestment ratio of TaiMed Biologics to understand how much of operating cash flow is reinvested back into capital assets.
TaiMed Biologics Market Cap History: 2015 to 2026
TaiMed Biologics's market capitalization history from 2015 to 2026. Data shows change from $2.20 Billion to $504.04 Million (-7.76% CAGR).
TaiMed Biologics Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how TaiMed Biologics's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.85x
TaiMed Biologics's market cap is 0.85 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.42 Billion | $2.08 Million | -$281.96 Million | 684.01x | N/A |
| 2017 | $1.58 Billion | $8.44 Million | -$524.55 Million | 187.03x | N/A |
| 2018 | $1.41 Billion | $241.04 Million | -$321.71 Million | 5.86x | N/A |
| 2019 | $845.19 Million | $704.50 Million | -$578.65 Million | 1.20x | N/A |
| 2020 | $717.26 Million | $722.49 Million | -$183.30 Million | 0.99x | N/A |
| 2021 | $602.12 Million | $413.44 Million | -$470.93 Million | 1.46x | N/A |
| 2022 | $602.97 Million | $563.01 Million | -$269.29 Million | 1.07x | N/A |
| 2023 | $699.35 Million | $491.78 Million | -$194.81 Million | 1.42x | N/A |
| 2024 | $733.46 Million | $610.16 Million | -$201.83 Million | 1.20x | N/A |
| 2025 | $521.95 Million | $611.35 Million | -$167.78 Million | 0.85x | N/A |
Competitor Companies of 4147 by Market Capitalization
Companies near TaiMed Biologics in the global market cap rankings as of August 6, 2026.
Key companies related to TaiMed Biologics by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #426 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #546 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #570 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $484.83 |
| #426 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $768.58 |
| #546 | Argen-X | BR:ARGX | $49.55 Billion | €748.60 |
| #570 | UCB SA | BR:UCB | $47.34 Billion | €229.20 |
TaiMed Biologics Historical Marketcap From 2015 to 2026
Between 2015 and today, TaiMed Biologics's market cap moved from $2.20 Billion to $ 504.04 Million, with a yearly change of -7.76%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$504.04 Million | -3.43% |
| 2025 | NT$521.95 Million | -28.84% |
| 2024 | NT$733.46 Million | +4.88% |
| 2023 | NT$699.35 Million | +15.98% |
| 2022 | NT$602.97 Million | +0.14% |
| 2021 | NT$602.12 Million | -16.05% |
| 2020 | NT$717.26 Million | -15.14% |
| 2019 | NT$845.19 Million | -40.12% |
| 2018 | NT$1.41 Billion | -10.54% |
| 2017 | NT$1.58 Billion | +11.11% |
| 2016 | NT$1.42 Billion | -35.34% |
| 2015 | NT$2.20 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 6th, 2026 the market cap of TaiMed Biologics was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $504.04 Million USD |
| MoneyControl | $504.04 Million USD |
| MarketWatch | $504.04 Million USD |
| marketcap.company | $504.04 Million USD |
| Reuters | $504.04 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About TaiMed Biologics
TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. The company develops and markets Trogarzo IV infusion and Trogarzo IV push, a monoclonal antibody for HIV treatment. It is also developing TMB-365, a monoclonal antibody used for HIV treatment and prevention which has completed a phase-1 clinica… Read more